No Data
No Data
Pacira BioSciences Independent Director Gary Pace Sells 85% Of Holding
We wouldn't blame Pacira BioSciences, Inc. (NASDAQ:PCRX) shareholders if they were a little worried about the fact that Gary Pace, the Independent Director recently netted about US$3.7m selling shares
Express News | Pacira Biosciences Announced That FDA Has Granted Regenerative Medicine Advanced Therapy Designation To Pcrx-201 (Enekinragene Inzadenovec), Gene Therapy Product For Knee Osteoarthritis
Pacira BioSciences Announces PCRX-201 Granted Regenerative Medicine Advance Therapy (RMAT) Designation for the Treatment of Osteoarthritis of the Knee
PDF Version -- PCRX-201 is the first gene therapy product candidate to receive RMAT designation for osteoarthritis ---- Designation supported by encouraging preliminary data from 72-patient Phase 1
Director Gary Pace Sells 119,323 Shares of Pacira BioSciences Inc (PCRX)
Pacira BioSciences(PCRX.US) Director Sells US$3.66 Million in Common Stocks
$Pacira BioSciences(PCRX.US)$ Director PACE GARY W sold 119.32K shares of Common Stocks on Mar 6, 7, 8, 2024 at an average price of $30.64 for a total value of $3.66 million.Source: Announcement What
Pacira Biosciences Insider Sold Shares Worth $3,656,226, According to a Recent SEC Filing
Gary W Pace, Director, on March 06, 2024, sold 119,323 shares in Pacira Biosciences (PCRX) for $3,656,226. Following the Form 4 filing with the SEC, Pace has control over a total of 22,127 shares of t
No Data